Clopidogrel Teva Generics B.V.

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

clopidogrel (as hydrochloride)

Available from:

Teva Pharma B.V.

ATC code:

B01AC04

INN (International Name):

clopidogrel

Therapeutic group:

Antitrombotska sredstva

Therapeutic area:

Peripheral Vascular Diseases; Acute Coronary Syndrome; Myocardial Infarction; Stroke

Therapeutic indications:

Клопидогрел prikazan odrasle za prevenciju атеротромботических događaja:pacijenti koji pate инфарктом miokarda (od nekoliko dana do manje od 35 dana), ishemijski moždani udar (od 7 dana prije manje od 6 mjeseci) ili instaliranim bolest perifernih arterija. Patients suffering from acute coronary syndrome:Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA). Porastom segmenta ST akutni infarkt miokarda, u kombinaciji s ASK u liječenju pacijenata koji imaju pravo na thrombolytic terapije. Za više informacija, molimo pogledajte odjeljak 5.

Product summary:

Revision: 3

Authorization status:

povučen

Authorization date:

2010-10-28

Patient Information leaflet

                                28
B. UPUTA O LIJEKU
29
UPUTA O LIJEKU: INFORMACIJA ZA KORISNIKA
KLOPIDOGREL TEVA GENERICS B.V.
_ _
75 MG FILMOM OBLOŽENE TABLETE
klopidogrel
PAŽLJIVO PROČITAJTE CIJELU UPUTU PRIJE NEGO ŠTO POČNETE UZIMATI
OVAJ LIJEK JER SADRŽI VAMA VAŽNE
PODATKE.
-
Sačuvajte ovu uputu. Možda ćete ju trebati ponovo pročitati.
-
Ako imate dodatnih pitanja, obratite se svom liječniku ili
ljekarniku.
-
Ovaj je lijek propisan samoVama. Nemojte ga davati drugima. Može im
naškoditi, čak i ako su
njihovi znakovi bolesti jednaki Vašima.
-
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti
liječika ili ljekarnika. To uključuje i
svaku moguću nuspojavu koja nije navedena u ovoj uputi. Vidjeti dio
4.
ŠTO SE NALAZI U OVOJ UPUTI:
1.
Što je Klopidogrel Teva Generics B.V. i za što se koristi
2.
Što morate znati prije nego što počnete uzmati Klopidogrel Teva
Generics B.V.
3.
Kako uzimati Klopidogrel Teva Generics B.V.
4.
Moguće nuspojave
5
Kako čuvati Klopidogrel Teva Generics B.V.
6.
Sadržaj pakiranja i druge informacije
1.
ŠTO JE KLOPIDOGREL TEVA GENERICS B.V. I ZA ŠTO SE KORISTI
Klopidogrel Teva Generics B.V. sadrži klopidogrel i pripada skupini
lijekova koji se nazivaju
antitrombocitni lijekovi. Trombociti su vrlo mala krvna tjelešca,
tzv. krvne pločice, koje se nakupljaju
tijekom zgrušavanja krvi. Sprječavanjem tog nakupljanja,
antitrombocitni lijekovi smanjuju
mogućnost stvaranja krvnih ugrušaka (proces zvan tromboza).
Klopidogrel Teva Generics B.V. uzimaju odrasli za sprječavanje
stvaranja krvnih ugrušaka (tromba) u
otvrdnutim krvnim žilama (arterijama), a taj poremećaj zove se
aterotromboza i može dovesti do
aterotrombotičkih događaja (kao što su moždani udar, srčani udar
ili smrt).
Klopidogrel Teva Generics B.V. Vam je propisan za sprječavanje
stvaranja krvnih ugrušaka i
smanjivanje opasnosti od ovih ozbiljnih događaja jer:
-
imate otvrdnuće arterija (koje se još zove ateroskleroza)
-
ste već imali srčani udar, moždani udar ili imate stanje koje se
zove bolest perifernih 
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
DODATAK I
SAŽETAK OPISA SVOJSTAVA LIJEKA
2
1.
NAZIV LIJEKA
Klopidogrel Teva Generics B.V. 75 mg filmom obložene tablete
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Jedna filmom obložena tableta sadrži 75 mg klopidogrela (u obliku
klopidogrel
klorida
).
Pomoćne tvari s poznatim učinkom:
Jedna filmom obložena tableta sadrži 13 mg hidrogeniranog
ricinusovog ulja.
Za cjeloviti popis pomoćnih tvari vidjeti dio 6.1.
3.
FARMACEUTSKI OBLIK
Filmom obložena tableta.
Ružičaste, okrugle i blago ispupčene, filmom obložene tablete.
4.
KLINIČKI PODACI
4.1
TERAPIJSKE INDIKACIJE
_ _
_Prevencija aterotrombotičkih događaja _
Klopidogrel je indiciran u:
odraslih bolesnika koji su pretrpjeli infarkt miokarda (u rasponu od
nekoliko do najviše
35 dana), ishemijski moždani udar (u rasponu od 7 dana do najviše 6
mjeseci) ili imaju
utvrđenu bolest perifernih arterija.
odraslih bolesnika koji boluju od akutnog koronarnog sindroma:
-
Akutni koronarni sindrom bez elevacije ST-segmenta (nestabilna angina
ili non-Q infarkt
miokarda), uključujući bolesnike koji se podvrgavaju ugradnji stenta
nakon perkutane
koronarne intervencije, u kombinaciji s acetilsalicilatnom kiselinom
(ASK).
-
Akutni infarkt miokarda s elevacijom ST-segmenta, u kombinaciji s ASK
u
medikamentozno liječenih bolesnika pogodnih za liječenje
trombolitičkom terapijom.
_Prevencija aterotrombotičkih i tromboembolijskih događaja kod
fibrilacije atrija _
U odraslih bolesnika s fibrilacijom atrija koji imaju najmanje jedan
faktor rizika za krvožilne događaje,
nisu podobni za terapiju antagonistima vitamina K (VKA) te imaju nizak
rizik od krvarenja,
klopidogrel je indiciran u kombinaciji s ASK za prevenciju
aterotrombotičkih i tromboembolijskih
događaja, uključujući moždani udar.
Za dodatne informacije vidjeti dio 5.1.
4.2
DOZIRANJE I NAČIN PRIMJENE
Doziranje
Odrasli i starije osobe
Klopidogrel se daje u jednokratnoj dnevnoj dozi od 75 mg.
Bolesnici s akutnim koronarnim sindromom:
Akutni koronarni sindrom bez elevacije ST-segmenta (nestabilna angina

                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 12-05-2014
Summary of Product characteristics Summary of Product characteristics Bulgarian 12-05-2014
Public Assessment Report Public Assessment Report Bulgarian 12-05-2014
Patient Information leaflet Patient Information leaflet Spanish 12-05-2014
Public Assessment Report Public Assessment Report Spanish 12-05-2014
Patient Information leaflet Patient Information leaflet Czech 12-05-2014
Public Assessment Report Public Assessment Report Czech 12-05-2014
Patient Information leaflet Patient Information leaflet Danish 12-05-2014
Public Assessment Report Public Assessment Report Danish 12-05-2014
Patient Information leaflet Patient Information leaflet German 12-05-2014
Public Assessment Report Public Assessment Report German 12-05-2014
Patient Information leaflet Patient Information leaflet Estonian 12-05-2014
Public Assessment Report Public Assessment Report Estonian 12-05-2014
Patient Information leaflet Patient Information leaflet Greek 12-05-2014
Public Assessment Report Public Assessment Report Greek 12-05-2014
Patient Information leaflet Patient Information leaflet English 12-05-2014
Public Assessment Report Public Assessment Report English 12-05-2014
Patient Information leaflet Patient Information leaflet French 12-05-2014
Public Assessment Report Public Assessment Report French 12-05-2014
Patient Information leaflet Patient Information leaflet Italian 12-05-2014
Public Assessment Report Public Assessment Report Italian 12-05-2014
Patient Information leaflet Patient Information leaflet Latvian 12-05-2014
Public Assessment Report Public Assessment Report Latvian 12-05-2014
Patient Information leaflet Patient Information leaflet Lithuanian 12-05-2014
Summary of Product characteristics Summary of Product characteristics Lithuanian 12-05-2014
Public Assessment Report Public Assessment Report Lithuanian 12-05-2014
Patient Information leaflet Patient Information leaflet Hungarian 12-05-2014
Summary of Product characteristics Summary of Product characteristics Hungarian 12-05-2014
Public Assessment Report Public Assessment Report Hungarian 12-05-2014
Patient Information leaflet Patient Information leaflet Maltese 12-05-2014
Public Assessment Report Public Assessment Report Maltese 12-05-2014
Patient Information leaflet Patient Information leaflet Dutch 12-05-2014
Public Assessment Report Public Assessment Report Dutch 12-05-2014
Patient Information leaflet Patient Information leaflet Polish 12-05-2014
Public Assessment Report Public Assessment Report Polish 12-05-2014
Patient Information leaflet Patient Information leaflet Portuguese 12-05-2014
Summary of Product characteristics Summary of Product characteristics Portuguese 12-05-2014
Public Assessment Report Public Assessment Report Portuguese 12-05-2014
Patient Information leaflet Patient Information leaflet Romanian 12-05-2014
Public Assessment Report Public Assessment Report Romanian 12-05-2014
Patient Information leaflet Patient Information leaflet Slovak 12-05-2014
Public Assessment Report Public Assessment Report Slovak 12-05-2014
Patient Information leaflet Patient Information leaflet Slovenian 12-05-2014
Summary of Product characteristics Summary of Product characteristics Slovenian 12-05-2014
Public Assessment Report Public Assessment Report Slovenian 12-05-2014
Patient Information leaflet Patient Information leaflet Finnish 12-05-2014
Public Assessment Report Public Assessment Report Finnish 12-05-2014
Patient Information leaflet Patient Information leaflet Swedish 12-05-2014
Public Assessment Report Public Assessment Report Swedish 12-05-2014
Patient Information leaflet Patient Information leaflet Norwegian 12-05-2014
Summary of Product characteristics Summary of Product characteristics Norwegian 12-05-2014
Patient Information leaflet Patient Information leaflet Icelandic 12-05-2014
Summary of Product characteristics Summary of Product characteristics Icelandic 12-05-2014

Search alerts related to this product